Gündüz K, Shields C L, Shields J A, Meadows A T, Gross N, Cater J, Needle M
Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pa., USA.
Arch Ophthalmol. 1998 Dec;116(12):1613-7. doi: 10.1001/archopht.116.12.1613.
To determine the outcome of chemoreduction treatment in patients with Reese-Ellsworth group V retinoblastoma.
Prospective analysis of 27 eyes in 22 patients with group V retinoblastoma treated with either 2- or 6-cycle chemoreduction and focal treatment methods (argon laser photocoagulation, transpupillary thermotherapy, cryotherapy, and plaque radiotherapy). The need for external beam irradiation and the eventual globe salvage rate were assessed. Median follow-up was 28 months.
There were 16 eyes in the 2-cycle chemoreduction treatment group and 11 eyes in the 6-cycle chemoreduction treatment group. No significant difference was noted between the 2 groups with respect to baseline patient and eye findings. After chemoreduction treatment, external beam irradiation was necessary in 12 (75%) of 16 eyes in the 2-cycle chemoreduction treatment group and in 4 (36%) of 11 eyes in the 6-cycle chemoreduction treatment group. There was no statistical difference between the 2- and 6-cycle chemoreduction treatment groups with respect to necessity for external beam irradiation (logistic regression analysis). All 4 eyes in the 2-cycle chemoreduction treatment group and 3 of 12 eyes in the 2-cycle chemoreduction treatment and irradiation group were eventually enucleated, the globe salvage rates being 0% and 75%, respectively. Two of 7 eyes in the 6-cycle chemoreduction treatment group and 1 of 4 eyes in the 6-cycle chemoreduction treatment and irradiation group were enucleated, the globe salvage rates being 71% and 75%, respectively. Except for the 2-cycle chemoreduction treatment group, in which the globe salvage rate was significantly lower (P = .03), there was no difference among the other 3 groups (2-cycle chemoreduction treatment and irradiation, 6-cycle chemoreduction treatment, and 6-cycle chemoreduction treatment and irradiation) with respect to globe salvage (logistic regression analysis).
Local tumor control of group V retinoblastoma is possible with 6-cycle chemoreduction and focal therapy when external beam irradiation is not used. A larger sample size is necessary to determine how often external beam irradiation can be avoided.
确定Reese-Ellsworth V 级视网膜母细胞瘤患者化疗减瘤治疗的结果。
对22例V级视网膜母细胞瘤患者的27只眼进行前瞻性分析,采用2周期或6周期化疗减瘤及局部治疗方法(氩激光光凝、经瞳孔温热疗法、冷冻疗法和敷贴放射疗法)。评估外照射的必要性及最终的眼球挽救率。中位随访时间为28个月。
2周期化疗减瘤治疗组有16只眼,6周期化疗减瘤治疗组有11只眼。两组在患者和眼部基线特征方面无显著差异。化疗减瘤治疗后,2周期化疗减瘤治疗组16只眼中有12只(75%)需要外照射,6周期化疗减瘤治疗组11只眼中有4只(36%)需要外照射。在是否需要外照射方面,2周期和6周期化疗减瘤治疗组之间无统计学差异(逻辑回归分析)。2周期化疗减瘤治疗组的4只眼中有4只最终被摘除眼球,2周期化疗减瘤治疗及照射组的12只眼中有3只最终被摘除眼球,眼球挽救率分别为0%和75%。6周期化疗减瘤治疗组的7只眼中有2只最终被摘除眼球,6周期化疗减瘤治疗及照射组的4只眼中有1只最终被摘除眼球,眼球挽救率分别为71%和75%。除2周期化疗减瘤治疗组的眼球挽救率显著较低(P = 0.03)外,其他3组(2周期化疗减瘤治疗及照射、6周期化疗减瘤治疗、6周期化疗减瘤治疗及照射)在眼球挽救方面无差异(逻辑回归分析)。
对于V级视网膜母细胞瘤,在不使用外照射的情况下,采用6周期化疗减瘤及局部治疗可实现局部肿瘤控制。需要更大样本量来确定可避免外照射的频率。